Compare AbbVie Inc (ABBV) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Booking Holdings Inc — how do they compare? AbbVie Inc trades at $253.53 (market cap $449.91B), while Booking Holdings Inc trades at $174.21 (market cap $140.99B). The key difference: AbbVie Inc is far larger — about 3.2× Booking Holdings Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | BKNG | |
|---|---|---|
Market Cap | $449.91B | $140.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $231.02 |
52-Week Low | $184.85 | $154.13 |
Enterprise Value | $513.38B | $143.91B |
Dividend Yield | 2.72% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Booking Holdings (BKNG) trades at $181.95, down 1.41% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with 2025 revenue of $26.92B and net income margin of 22.23%, though Q2 2026 earnings are pending. Analyst consensus remains strongly positive with 64% buy ratings and a $225 price target, representing 24% upside potential from current levels.
BKNG presents a compelling investment case with robust cash flow generation ($9.4B operating cash flow in 2025) and dominant market position, though risks include high debt levels (64% debt-to-asset ratio) and AI disruption concerns. The stock's current valuation at 23.87 P/E appears reasonable given growth prospects, with upcoming Q2 earnings on August 4 serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
